ARTELO BIOSCIENCES INC C/WTS 25/06/2024(TO PUR COM) ARTLW 深 沪
等待开盘 08-21 09:30:00 美东时间
0.0056
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0056
- 总市值 1.87万
- 52周最高 0.1498
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.005
- 委 比 0.00%
- 总股本 334.74万
- 历史最高 1.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Says USPTO Issues Notice Of Allowance For U.S. Patent Application Covering Intended Commercial Formulation Of ART27.13, Peripherally Selective Cannabinoid Agonist Currently In Phase 2 Studies
The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipi...
08-17 20:56
Artelo Biosciences Q2 EPS $(0.89) Up From $(16.83) YoY
Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.89) per share. This is a 94.71 percent increase over losses of $(16.83) per share from the same period last year.
08-13 20:21
Artelo Biosciences Says First Patient Dosed In DREAM Study Evaluating Effects Of ART27.13 In Patients With Glaucoma Or Ocular Hypertension; Initial DREAM Study Results Anticipated In Q4
Investigator-led study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology Initial DREAM Study Results Anticipated in Q4 2026 SOLANA BEACH, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmace...
08-10 20:49
Artelo Biosciences Announces Publication Of Article 'Evaluating The Pharmacokinetics, Efficacy, And Safety Of Low Dose Cannabidiol' In The British Journal Of Clinical Pharmacology
The peer-reviewed evaluation analyzed the efficacy, pharmacokinetics, and safety data obtained from over 50 studies using low-dose cannabidiol (CBD) commonly found in over-the-counter products — and exposes critical limitations and risks of these non-prescription CBD preparations at the doses admini...
07-22 20:41
Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences' ART27.13 shows promise in treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer. Nonclinical studies demonstrate its ability to reduce pain-related behaviors and improve body weight and activity levels. Interim results from the CAReS Phase 2 trial highlight its potential broader utility in cancer supportive care, addressing both anorexia cachexia syndrome and chemotherapy-induc...
07-13 13:02
Artelo Biosciences Announces Two Presentations Supporting Development Of ART26.12, Its Selective Fatty Acid Binding Protein 5 Inhibitor
The presentations include results from the Phase 1 clinical study of ART26.12 as well as new biomarker analyses designed to identify indicators of target engagement and pharmacological activity in healthy volunteers. During the first of two presentations, Professor Saoirse E. O'Sullivan, Vice Presid...
06-29 20:48
Artelo Biosciences Presents Metabolite Identification And Profiling Data From Its FABP Inhibitor Candidate ART26.12; Tracks Three Metabolites From Plasma Of Healthy Volunteers Given Single 900 Mg Oral Dose Of ART26.12
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, announces that Myles Osborn, Lead Medicina...
06-10 19:40
Artelo Biosciences Launches Flexible At-The-Market Offering
The latest announcement is out from Artelo Biosciences ( ($ARTL) ). On May 26, ...
05-28 05:37
